Prostate-specific membrane antigen (PSMA)–negative neuroendocrine prostate cancer
(PCa) is a subtype of PCa likely to be lethal, with limited clinical diagnostic and therapeutic …

PSMA-negative neuroendocrine prostate cancer (NEPC) is likely to be a lethal subtype of
prostate cancer (PCa) with limited clinical diagnostic and therapeutic options. High …

Introduction Despite recent developments in the diagnosis and treatment of prostate cancer,
the advanced stages still have poor survival rates. This warrants further exploration of …

Background: The aim of the study was to perform PET imaging and radiotherapy with a
novel neurotensin derivative for neurotensin receptor 1 (NTSR-1)-positive tumors in an …

Introduction Over the last decades, multiple peptide receptors were recognized as potential
diagnostic and therapeutic targets in nuclear medicine. 68 Ga-NT-20.3 radiopharmaceutical …

Introduction: Neurotensin receptor 1 (NTR-1) is expressed and activated in prostate cancer
cells. In this study, we explore the NTR expression in normal mouse tissues and study the …

Overexpression of the high affinity neurotensin receptor 1 (NTSR1), demonstrated in several
human cancers, has been proposed as a new marker for human ductal pancreatic …

Overexpression of neurotensin receptors (NTRs) has been suggested to play important roles
in the growth and survival of a variety of tumor types. The aim of this study is to develop a …

Neurotensin receptor 1 (NTSR1) is overexpressed in human pancreatic ductal
adenocarcinoma (PDAC). Specific noninvasive positron-emission tomography (PET) …

The NTS1 has emerged as an interesting target for molecular imaging and targeted
endoradiotherapy (“theranostics”) due to its overexpression in a variety of tumors, such as …